Cox
T, Lachmann R, Hollak C, et al. Novel oral treatment of
Gaucher's disease with N-butyldeoxynojirimycin (OGT 918)
to
decrease substrate biosynthesis. Lancet. 2000;355:1481–1485.
Elstein D, Hollak C, Aerts JM, et
al. Sustained therapeutic effects of oral miglustat (Zavesca,
N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
J Inherit Metab Dis. 2004;27:757–766.
Heitner R, Elstein D,
Aerts J, et al. Low-dose N-butyldeoxynojirimycin (OGT 918)
for
type I Gaucher disease. Blood Cells Mol Dis. 2002;28:127–133.
Downloads |
